aid: hexagon-bio
name: Hexagon Bio
description: 'Hexagon Bio is a Menlo Park, California biotechnology company developing novel payloads for
  antibody-drug conjugates (ADCs) in oncology. The company designs next-generation ADC payloads intended
  to overcome resistance to current payloads and to expand the range of cancer indications ADCs can treat.
  Backed by SoftBank Vision Fund, Hexagon Bio operates a therapeutics pipeline and research platform rather
  than a public developer program: it publishes no API, SDK, or developer documentation surface. This
  profile was surfaced as a portfolio-company lead and enriched from Hexagon Bio''s own public website
  (company, pipeline, science/platform, and news pages).'
url: https://raw.githubusercontent.com/api-evangelist/hexagon-bio/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.hexagonbio.com/favicon.ico
x-type: company
x-source: vc-portfolio
x-backed-by:
- softbank-vision-fund
x-tier: stub
x-tier-reason: portfolio-lead
x-website: https://www.hexagonbio.com
x-no-developer-surface: true
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Health Tech
- Biotechnology
- Oncology
- Antibody-Drug Conjugates
- Drug Discovery
- Therapeutics
apis: []
common:
- type: DomainSecurity
  url: security/hexagon-bio-domain-security.yml
- type: Website
  url: https://www.hexagonbio.com
- type: Blog
  url: https://www.hexagonbio.com/news/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence